Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 24 2025
0mins
Source: Benzinga
Nektar Therapeutics Stock Surge: Shares of Nektar Therapeutics rose 30.3% in pre-market trading after announcing the release date for top-line data from its Phase 2b REZOLVE-AD clinical trial on June 24, 2025.
Market Movements: Several stocks experienced significant pre-market movements, with iBio, Inc. gaining 55.8% and Upexi, Inc. dropping 62.3%, reflecting a mix of gains and losses across various companies.
Analyst Views on UPXI
Wall Street analysts forecast UPXI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for UPXI is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.980
Low
6.00
Averages
6.00
High
6.00
Current: 1.980
Low
6.00
Averages
6.00
High
6.00
About UPXI
Upexi, Inc. is a solana-focused treasury company. The Company is a brand owner specializing in the development, manufacturing and distribution of consumer products with diversification into the cryptocurrency space. The Company’s brands include Lucky Tail, PRAX, and Cure Mushrooms. Lucky Tail is a pet care product brand that provides products from grooming tools to nutritional products. Cure Mushrooms is a full line of medicinal mushroom products, designed by effect for consumers, which offers mushroom extracts in tinctures and gummies. PRAX is a full line of medicinal mushroom products, designed by effect for consumers, which are cultivated, extracted, and produced in the United States. Its products are distributed in the United States of America and internationally through multiple entities and managed through locations in Florida.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
